NEW YORK, Sept. 7 /PRNewswire-USNewswire/ -- AMDeC, the Academy for Medical Development and Collaboration, announced today that NuGEN Technologies, Inc., developer of cutting-edge sample preparation technology for genomic analysis, has joined AMDeC's Vendor Partnership Program. The Vendor Partnership Program is aimed at strengthening science through efficiency and collaboration while providing tremendous cost savings on products for AMDeC member academic medical institutions.
NuGEN is the newest strategic partner to offer significant savings on its products to AMDeC's consortium of 24 academic biomedical research institutions. Designed for RNA and DNA analysis in clinical research, biomarker or signature discovery, NuGEN's proprietary sample preparation technology enables analysis of virtually any sample type for advanced genetic analysis on platforms such as next-generation sequencing and microarrays. In addition, as part of the Vendor Partnership Program, AMDeC member researchers can participate in NuGEN-specific laboratory training events and receive priority NuGEN technical support.
AMDeC's Vendor Partnership Program identifies high-need technologies in order to offer AMDeC member institutions advanced technology access and discounted product pricing. These valuable partnerships, negotiated through AMDeC on behalf of the entire consortium, leverage AMDeC's collective purchasing power and lead to greater cost efficiencies, economies of scale, early access to the newest biomedical technologies and increased grant competitiveness for AMDeC member institutions. NuGEN is the latest of a growing list of technology vendors participating in the program.
"It is NuGEN's mission to give our customers the latest technology tools that enable breakthrough discoveries and research," said Elizabeth Hutt, Chief Executive Officer of NuGEN. "As a part of AMDeC's Vendor Partnership Program, NuGEN can expand our current relationships and reach new academic customers, facilitating critical scientific advancements."
"We are extremely pleased to bring NuGEN together in such a collaborative program with academia," said Maria Mitchell, Ph.D., President of AMDeC. "The importance of linking industry to academic research has never been greater in the biosciences."
Information related to all AMDeC's Vendor Partnerships can be found on AMDeC F.I.R.S.T.(TM) (Facilities Instrumentation Resources Services & Technologies). AMDeC F.I.R.S.T. is a user friendly, secure online platform that provides real-time information on laboratories, instruments, resources, services and technologies available for immediate use on a fee-for-service basis. It serves as a single point-of-entry to a comprehensive registry of core facilities services and instruments across the AMDeC consortium. It also details all information associated with AMDeC's Vendor Partnerships. Access is available to AMDeC members at no cost. Interested parties should log on to www.amdec.org for more information.
Established in 1997, the Academy for Medical Development & Collaboration, AMDeC, is a consortium of 24 pre-eminent academic biomedical research institutions. In its 13 year history AMDeC has led the way towards team science, resource sharing efforts, member services focused on cost savings and technology access, and private sector participation with academia. AMDeC has recently debuted AMDeC F.I.R.S.T.(TM), the first real-time online registry of biomedical research service and resources in the consortium.
NuGEN accelerates the pursuit of the unimaginable. The company's portfolio of innovative sample preparation technologies provides scientists with new tools to access genetic information from previously unexplorable biological samples. NuGEN's platform-agnostic reagent solutions amplify and prepare DNA and RNA samples with fast, streamlined workflows for analysis on advanced platforms including next-generation sequencing and microarrays. With the capability to support data extraction from any sample type, NuGEN is fueling discoveries that improve the quality of human life by enhancing health management in areas ranging from cancer to infectious disease.
Copyright©2010 PR Newswire.
All rights reserved